The hyaluronic acid receptor for endocytosis (HARE)/ Stabilin-2 is the primary systemic scavenger receptor for hyaluronan (HA), the chondroitin sulfates (CS), dermatan sulfate (DS), and nonglycosaminoglycan (GAG) ligands such as acetylated low-density lipoprotein (AcLDL), pro-collagen propeptides, and advanced glycation end products. We recently discovered that HARE is also a systemic scavenger receptor for heparin ( 
Introduction
Scavenger receptors are present in a variety of tissues, particularly the reticuloendothelial systems that clear the lymph and plasma of metabolic waste products and macromolecular debris. Currently, scavenger receptors are organized into five classes and one unclassified group (Yuasa and Watanabe 2003) . Scavenger receptors can be broadly expressed or tissue specific, e.g., ranging from MSR1, which is found in macrophages in diverse tissues , to Macrosialin/CD68, which is expressed only on macrophages found in the liver and peritoneum (Yoshida et al. 1998 ). The one common feature among scavenger receptors of the various classes is that they all bind low-density lipoprotein (LDL) and/or one or more naturally occurring LDL derivatives: acetylated LDL (AcLDL) and oxidized LDL (oxLDL). Most of these receptors also bind other classical polyanionic ligands such as maleylated bovine serum albumin (BSA), dextran sulfate, chondroitin sulfate (CS), fucoidan, and polyribonucleotides (e.g., poly I, poly G). Although not all of these latter ligands occur naturally, they all share features with natural analogs that facilitate high affinity and specific binding to their respective receptors .
In this report, we characterize the ligand-binding profile of the hyaluronic acid (HA) receptor for endocytosis (HARE), also known as Stabilin-2/FEEL-2, which is a scavenger receptor that is highly expressed in the sinusoidal, or noncontiguous, endothelium of liver, lymph node, and spleen (Laurent and Fraser 1992) . Fraser et al. (1983) first identified a scavenger clearance activity for HA when they injected mice with 14 C-HA and found it sequestered in these organs. In addition, HARE is found in oviduct, corneal and lens epithelium, heart valve mesenchymal cells, ependymal cells lining ventricles in brain, and epithelial cells covering renal papillae (Falkowski et al. 2003) . The rat receptor was identified, purified, and characterized first (Yannariello-Brown et al. 1997; Zhou et al. 1999) . Human HARE was later cloned and purified (Politz et al. 2002; Zhou et al. 2003) , and then characterized in stable cell lines (Harris et al. 2004 (Harris et al. , 2007 . The same protein was initially identified in the human genome database as a Stabilin-1 analog of unknown function (Politz et al. 2002) . Human HARE is a 2551-amino-acid, 315 kDa, type-1 transmembrane receptor expressed on the cell surface and intracellular (e.g., endocytic) compartments. Two HARE isoforms (not splice variants) of different mass (e.g., 190 kDa and 315 kDa in human) are found in native tissues (Zhou et al. 1999 (Zhou et al. , 2003 Weigel et al. 2002) . During biosynthesis and exocytosis in cells stably expressing full-length human HARE cDNA, a minor subset of the 315 kDa receptor pool is proteolytically cleaved to create the 190 kDa HARE, the C-terminal 1416 aa of the 315-HARE HA and Hep bind to distinct sites in human 190-HARE protein (Harris et al. 2007) . Although the mechanism and biological reasons for this protein processing are not yet known, both forms of the receptor are functional (Harris et al. 2004 (Harris et al. , 2007 and occur in the same tissues.
HARE recognizes a host of different ligands, including HA (Yannariello-Brown et al. 1997; Politz et al. 2002) , collagen N-terminal pro-peptides (Hansen et al. 2005) , advanced glycation endproducts (Tamura et al. 2003) , AcLDL (Adachi and Tsujimoto 2002) , CS A-E (Harris et al. 2004) , phosphatidylserine (Park et al. 2008) , and αMβ2 integrin (Jung et al. 2007 ). We found recently that HARE is also a clearance receptor for heparin (Hep) ). The receptor is composed of modular repeats of EGF, EGF-like, and Fasciclin domains. A defining feature of HARE is its Link domain, situated near the transmembrane domain, which closely resembles Link domains in other HA-binding proteins such as TSG-6, CD44, and aggrecan (Day and Prestwich 2002) .
Our goals in this study were to define which ligands compete with one another, how the binding of one ligand affects the other, and the relative organization within HARE of binding sites for the different ligands. We primarily studied the 190 kDa HA receptor for endocytosis , since it has higher expression as a cell surface receptor or secreted ecto-domain than the 315 kDa HA receptor for endocytosis (315-HARE). Both isoforms have very similar, if not identical, ligand-binding profiles.
Results

Antibody inhibition of Hep binding to HARE
hHARE, encoded by the STAB2 gene, specifically binds to HA and multiple CS types (Zhou et al. 2003; Harris et al. 2004 Harris et al. , 2007 . We recently reported that HARE/Stab-2 is also the clearance or scavenger receptor for circulating Hep . Although Hep binds to many proteins, including coagulation factors, no specific receptor for Hep clearance had been identified. Specific Hep binding to purified recombinantsecreted 190-HARE ecto-domain was blocked by a pAb against the purified s190-HARE protein ( Figure 1A ). At the maximum dose, ∼70% of B-Hep binding to s190-HARE was blocked. In contrast, pre-immune Ab at the same concentration did not block Hep binding (not shown). Next, we evaluated the internalization of B-Hep and B-HA by 190-HARE cells in the presence of a saturating amount (30 µg/mL) of rabbit anti-s190-HARE pAb or pre-immune IgG ( Figure 1B ). Anti-s190-HARE, but not pre-immune, Ab inhibited the uptake of 125 I-SA-B-Hep into 190-HARE cells by ∼58% (gray bars), whereas 125 I-SA-B-HA uptake was inhibited ∼90% (black bars). In both cases, preimmune IgG showed little or no inhibition. The differential inhibition of Hep versus HA binding by the same anti-HARE Ab indicates the possibility that these glycosaminoglycans (GAGs) bind to different sites.
HA and Hep bind to distinct and separate sites in 190-HARE
To determine if HA and Hep bind to the same, to overlapping, or to different sites on 190-HARE, we used an ELISAlike assay with B-GAGs and unlabeled GAGs as competitors ( Figure 2A ). We used a saturating concentration of B-HA to occupy all binding sites and saturate the HA response signal for this assay (black bar). In parallel, an amount of B-Hep that was not at saturation was used to produce a response signal lower In ELISA-like assays, immobilized purified s190-HARE was incubated for 15 min with increasing concentrations of anti-s190-HARE polyclonal IgG. Following three washes, increasing concentrations of anti-s190-HARE polyclonal IgG and 100 nM B-Hep mixtures were added to the wells and incubated for 2 h at 37 • C. After washing and detection with SA-AP, the A 405 values were quantified and expressed as the mean ± SE (n = 4). (B) 190-HARE cells were treated as in Materials and methods and then incubated with 30 µg/mL pre-immune IgG or anti-s190-HARE immune IgG for 15 min at 37 • C, prior to the addition of 30 µg/mL pre-immune or anti-s190-HARE IgG in combination with either 125 I-SA-B-Hep (gray bars) or 125 I-SA-B-HA (black bars). The cells were allowed to endocytose GAG complexes for 4 h, washed with HBSS, and lysed with 0.3 N NaOH. Radioactivity and protein were quantified. The values are means ± SE (n = 3) expressed as the cell-associated specific CPM/µg protein.
than the HA signal (white bar). When these amounts of B-HA and B-Hep were incubated together, they produced an additive signal (upper gray bar) that could be attenuated to the B-HAalone signal in the presence of unlabeled Hep (lower gray bar). These results strongly indicate that Hep and HA do not bind within the same HARE-binding site and that, unlike TSG-6 which also binds both ligands separately, HARE can bind HA and Hep simultaneously.
To confirm this conclusion based on results from the ELISAlike assay, we performed similar experiments in cells stably expressing either the smaller 190-HARE isoform alone ( Figure 2B ) or the 315-HARE ( Figure 2C) ; although the cDNA encodes full-length 315-HARE, these cells also make minor amounts of 190-HARE (Harris et al. 2007 ). The cellular accumulation of 125 I-SA-B-GAG in this assay monitors binding to HARE and receptor-mediated endocytosis. In these experiments, the first set of wells contained only saturating amounts Assays were all performed simultaneously and bound B-GAG was detected using SA-alkaline phosphatase and p-nitrophenylphosphate. The A 405 values are expressed as mean ± SE (n = 3). For endocytosis assays, 190-HARE (B) and 315-HARE (C) cells were used to determine HA and Hep uptake and competition. 125 I-SA-B-GAG complexes were prepared and then incubated with cells as described in Materials and methods. Cells were incubated either with one labeled B-GAG complex alone (black bars) and the other unlabeled GAG (dark gray bars), or with both labeled B-GAGs without (light gray bar) and with one unlabeled GAG as competitor (white bars). All sample wells contained equal amounts of 125 I-SA. After 4 h at 37 • C, the cells were washed with HBSS three times, lysed in NaOH, and radioactivity and protein were determined. Values are the mean ± SE (n = 3) expressed as the specific CPM/µg protein. Although one ligand might not bind to the other ligandbinding site, occupancy of one site might alter (e.g., in an allosteric-like manner) the binding of the second ligand to its site. In the third set of wells (Figure 2B and C; light gray bar), we added the 125 I-SA-B-HA and 125 I-SA-B-Hep mixtures together to determine if both GAGs could bind and be internalized noncompetitively, as in Figure 2A , or competitively (e.g., as in the case of TSG-6). The signals from the combined mixtures were additive (i.e., the sum of the signals obtained with each B-GAG alone), confirming that both GAGs bound to HARE independently and noncompetitively. A fourth set of wells contained both 125 I-SA-B-GAG mixtures plus a 20-fold excess concentration of one unlabeled GAG ( 
Sulfate groups are required for Hep binding with HARE
Since the sulfation of GAGs increases their negative charge and creates multiple types of disaccharide units, we assessed the 
Dermatan sulfate (DS) partially inhibits HARE-mediated endocytosis of B-Hep
We next focused on whether any of the other GAGs compete with Hep and HA for binding and endocytosis mediated by HARE. Since both Hep and DS contain iduronic acid and multiple sulfation sites, we tested if these two GAGs could interact with the same receptor-binding site ( 
DS competes with both HA and Hep, which do not compete with each other
Next, we used the ELISA-like assay to examine the relationship among HA-, Hep-, and DS-binding sites on the purified s190-HARE. First, we tested the binding of B-HA in the presence of unlabeled HA, DS, or Hep ( Figure 6 ; black bars). As expected, HA competed effectively (68%), but DS or Hep did not. Second, we tested the binding of B-Hep to s190-HARE in the presence of unlabeled HA or DS ( Figure 6 ; gray bars). B-Hep binding was reduced by Hep (>98%) or DS (71%), but not by HA. The lack of cross-competition between HA and Hep binding to HARE further supports the conclusion that they bind to separate and distinct sites. Third, we tested B-DS binding to s190-HARE in the presence of unlabeled Hep or DS (Figure 6 ; white bars). B-DS binding was well competed by DS (>97%) and Hep (>99%) but only partially blocked by HA (30%). The results indicate that DS binds within or near the Hep-binding site and also to a lesser degree with the HA-binding site. A similar result was also obtained with 190-HARE or 315-HARE cells incubated with 125 I-HA and excess DS; a small, but significant, amount of 125 I-HA uptake was competed by DS (Harris et al. 2007 ).
Dextran sulfate (Dx-S) and CS-E inhibit Hep binding to purified s190-HARE
Dx-S is a synthetic polyanionic polysaccharide, whose degree of sulfation can be varied, and that can mimic some of the sulfation patterns and properties of a GAG, including Hep. In ELISA-like assays with purified s190-HARE, B-Hep binding was progressively inhibited by increasing concentrations of Dx-S ( Figure 7A ), indicating that Dx-S competes with Hep for a common s190-HARE-binding site. In fact, for equivalent molar amounts, Dx-S was a better competitor for B-Hep binding than unlabeled Hep. This suggests that the right sulfation pattern needed for HARE binding occurs more frequently in Dx-S than in Hep, even though the mass of Dx-S is approximately half of the Hep mass.
We used ELISA-like assays to assess whether CSs A-E, chondroitin (Chon), or heparan sulfate (HS) can also compete for the binding of B-Hep to s190-HARE ( Figure 7B ). The only GAG that significantly decreased B-Hep binding, other than Hep and DS (CS-B), was CS-E (chondroitin 4,6-disulfate); no significant competition was seen with Chon, CS-A, CS-C, CS-D, HS, or HA. These results indicate that negative charge density is not the only, or even the key, factor involved with Hep binding, but rather the spatial organization and orientation of charge groups likely determines how well the molecule fits into the Hep-binding site(s) of HARE. We also used these ELISA-like and cell-based endocytosis assays to determine if keratan sulfate (KS) affects B-Hep binding and found that KS, like HS and HA, does not compete for B-Hep binding to HARE (not shown).
AcLDL endocytosis by 190-HARE cells is competed by Hep and DS
We compared the ability of EV and 190-HARE cells to endocytose 125 I-AcLDL and found that the level of nonspecific binding with excess AcLDL was moderately low (equivalent in both cell lines and ∼25% of total HARE-mediated binding). Nonspecific endocytosis was subtracted from the total endocytosis to obtain 190-HARE-mediated specific endocytosis of 125 I-AcLDL Figure 1B with an endocytosis medium containing 2 µg/mL 125 I-AcLDL for 4 h at 37 • C. To account for nonspecific binding and endocytosis of 125 I-AcLDL, the average cell-associated radioactivity of EV cells was subtracted from the 190-HARE cell values. To test the competition by other GAGs for 125 I-AcLDL binding and endocytosis, 190-HARE cells were also incubated with excess (4 µM) unlabeled GAG as indicated. The mean ± SE (n = 3) values for the specific cell-associated CPM/µg cell lysate protein were determined as in Figure 1B and Materials and methods.
( Figure 8 , black bar). In the same experiment, we assessed the competitive abilities of unlabeled Hep, HS, DS, Dx, and Dx-S (Figure 8 , gray bars). Hep and Dx-S, which compete with each other as noted above, inhibited 125 I-AcLDL endocytosis by 60% and 95%, respectively, whereas DS reduced 125 I-AcLDL internalization by only 20%. HS and nonsulfated dextran had no effect on 125 I-AcLDL binding and endocytosis by HARE. Thus, although HS and Hep share many similarities, the results confirm that HS does not bind to HARE at the HA-binding site or the Hep-binding site, which is also shared by Dx-S and AcLDL.
Endocytosis of AcLDL by 190-HARE cells is only partially competed by Hep and DS
Earlier results showed that DS blocks HA uptake only partially by 190-HARE cells (Harris et al. 2004 (Harris et al. , 2007 . Based on results in Figure 7 and Figure 8 , DS also competed for Hep and AcLDL binding, with different apparent affinities for HARE. Since DS and Hep bind to the same region of HARE, we tested how increasing concentrations of each affected the binding and endocytosis of a fixed amount of 125 I-AcLDL by 190-HARE cells (Figure 9 ). Both Hep and DS displayed similar dose-response inhibition curves that saturated at ∼0.5 µM and resulted in only partial displacement of 125 I-AcLDL. Maximum inhibition by DS and Hep plateaued at 25% and 50%, respectively, although the apparent K i values were similar at ∼50 nM. These results indicate that the three ligands (DS, Hep, and AcLDL) have both common overlapping and unique sites of interaction with HARE. Figure 1B . (A) Hep or DS was added, to the indicated concentration, to cells in the endocytosis medium containing 2 µg/mL 125 I-AcLDL. After 3 h at 37 • C, the cells were washed, lysed, and radioactivity and protein were determined. Values are the mean ± SE (n = 3) cell-associated CPM/µg cell lysate protein. Figure 1B and Materials and methods. Preformed complexes (100 nM) of 125 I-SA-B-HA (solid bars) or 125 I-SA-B-Hep (cross-hatched bars) were prepared and added to cells with or without 50 µg/mL AcLDL, as indicated. After 4 h at 37 • C, cell-associated CPM/µg cell lysate protein values (mean ± SE; n = 3) were measured as noted in Figure 1B and Materials and methods.
AcLDL blocks endocytosis of Hep, but not HA, by 190-HARE cells
or without unlabeled AcLDL. In 190-HARE cells, AcLDL did not decrease B-HA uptake, but reduced B-Hep uptake by >50%. Predictably, AcLDL also decreased B-Hep uptake in 190-HARE( Link) cells. Additionally, the small amount of B-HA accumulation by 190-HARE( Link) cells was not affected by AcLDL. We conclude from this experiment that AcLDL binds within the Hep-binding domain, but not the HA-binding Link domain. Furthermore, the residual HA-binding site in the 190-HARE( Link) mutant receptor also appears to be distinct from the AcLDL-binding site.
Discussion
Recently, we showed that HARE specifically binds with Hep . It is likely that HARE is the primary scavenger receptor for removing Hep from blood and lymph fluid. In this report, we show for the first time that HARE can (ii) AcLDL specifically binds HARE and binding is competed robustly by Hep or Dx-S, partially by DS, but not at all by HA; (iii) at least 90% of the HA-binding activity is due to the HARE Link domain and the remaining ∼10% binds to HARE at an unknown site; (iv) HARE lacking the HA-binding Link domain still binds normally with AcLDL or Hep; and (v) only DS and CS-E bind within parts of both the Hep-and HA-binding sites. Previous results showed that CS-A, CS-C, and CS-D all bind within the HA-binding site of HARE (Harris et al. 2004 (Harris et al. , 2007 , and the present results confirm that the Link domain is the major HA-binding site. The Link domain is also required to bind these CS types (data not shown).
Thus, our results show that HARE/Stabilin-2 specifically binds with AcLDL and seven different GAGs (HA, Hep, CS-A, CS-C, CS-D, CS-E, and DS), as well as the synthetic glycan, Dx-S, at two primary independent sites. Based on experiments outlined in this and previous reports, our current model for the organization of these multiple ligand-binding sites illustrates that the HA-binding (Link) domain is completely separate from the Hep-and AcLDL-binding domain (Figure 11 ). Hep and HA bind to mutually inclusive sites (the two largest nonoverlapping circles, Figure 11 ) within the 190-HARE isoform ( Figures 1B  and 2 ). Although it was assumed that the Link domain is the primary HA-binding site, this is the first report to demonstrate this experimentally ( Figure 3A) . Figure 3B also (Figures 5, 6 , and 7B) and HA (Figure 6 ; Harris et al. 2004 Harris et al. , 2007 although there is a higher level of competition with Hep than with HA ( Figure 6 ). CS-E binding to HARE is competed by both Hep ( Figure 7B ) and HA (Harris et al. 2004 ) to the same extent; thus bound CS-E may span both binding sites equally. It is also possible that DS or CS-E bind independently, and with different affinities, to parts of the Hep and HA binding sites. CS-A, CS-C, and CS-D all compete only with HA (Harris et al. 2004) and not Hep ( Figure 7B ). Others reported that HARE is a scavenger for AcLDL (Adachi and Tsujimoto 2002; Tamura et al. 2003) . In our direct labeling and competition studies, AcLDL competed with Hep (Figures 8 and 10) , DS (Figures 8 and 9 ), but not with HA ( Figure 10 ). AcLDL binding was also competed with Dx-S (Figure 8 ), a competitor for Hep binding ( Figure 7A ), but not with HS (Figure 8) . A portion of the AcLDL-binding site lies outside of both the Hep and HA sites (Figure 9 ) (Figure 11 , circles).
The in silico structure of the HARE/Stabilin-2 Link domain is predicted based on the structures of other Link-containing proteins . Link domains contain a groove for the HA strand to slip into and interact with three Tyr (aromatic) and two Lys/Arg (basic) residues. The Hep-binding site of HARE is still unknown and may be situated within the EGF domains of the protein. It does not appear to be located within a separate binding groove of the Link domain, as seen with TSG-6 . In TSG-6, HA and Hep or HS bind within the Link domain in separate binding grooves. When Hep or HS bind, there is a conformational change in the protein that prevents HA from binding and likewise, if HA binds then the Hep-or HS-binding site is inactive. Thus, HA and Hep both cannot bind simultaneously to TSG-6 . In contrast, despite the high homology (48% identical and 64% similar) between the TSG-6 and HARE Link domains, we do not see a contribution to Hep-binding activity by the HARE Link domain. In space-filling models of the TSG-6 Link domain, the Hep saccharide chain is positioned to interact with basic residues at positions 34, 54, and 56 (Link domain numbering); of these residues, only R56 is present in the Link domain of HARE. Other amino acids possibly involved in electrostatic interactions with the sulfate groups of Hep are present in Link domains of both HARE (R20, K41, K72, K84) and TSG-6 (K20, K41, K72, R84).
The HARE Link domain functions differently than that of TSG-6, since both HA and Hep bind with HARE simultaneously, and 190-HARE( Link) binds with Hep at least as well as the wildtype receptor. Another difference between the HARE and TSG-6 Link domains is that both Hep and HS bind to the same site on TSG-6 Link, but HARE Link binds only HA and not HS ( Figure 7B ; Mahoney et al. 2005) . Direct binding assays found no HS-binding activity in purified s190-HARE or membrane-bound 190-HARE. One difference between Hep and HS is that Hep is more highly sulfated. Hep sulfation occurs almost entirely along the sugar backbone in contrast to HS, which contains islands of high sulfation between long stretches of low sulfation (Bame 2001) . Compared to HA, Hep contains IdoA(2S)-(α1,4)-GlcNS(6S) in greater abundance than IdoA-(α1,4)-GlcNS(6S) and IdoA(2S)-(α1,4)GlcNS, which helps to give Hep a higher sulfation density. GlcNS(6S) residues of Hep also promote more of the rare 3-O sulfation of GlcNS(6S), to form GlcNS(3S,6S), than in HS (Rabenstein 2002) . In contrast, HS contains more GlcNAc than GlcNS, rarely any 3-O sulfate, and the ratio per disaccaride of HS O-sulfate to Hep O-/N-sulfate is 0.2-0.7:2.4. We assume that the specific binding of HARE to Hep, but not HS, involves some of these structural differences between HS and Hep sulfation.
The full-length HARE/Stabilin-2 receptor contains four Cysrich EGF clusters and seven Fasciclin domains. The 190-HARE encoding region contains the two C-terminal EGF clusters and four of the Fasciclin domains. Since both the full-length 315 kDa and 190 kDa HARE receptor ecto-domains bind Hep to the same extent and the same affinity , the Hep-binding site(s) must be contained within the 190-HAREencoding region. Fasciclin domains may not contribute to the Hep-binding sites, since the Fasciclin domain is involved with binding αMβ2 integrins (Jung et al. 2007 ). The integrin-binding Fascilin domains of the receptor may serve a general adhesive function, since cells with high expression of surface HARE exhibit greater cell-cell and cell-substratum adhesion than EV cells (not shown).
Heparosan, which is the Hep precursor polymer and lacks negatively charged sulfate groups or epimerized uronic acids, does not bind with HARE. Likewise, Dx-S competes with Hep for HARE binding, whereas the unsulfated dextran does not. On the other hand, charged residues alone cannot account for all the binding specificity or activity of HARE for Hep, Dx-S, and DS polymers. If that were the case, then all of the CS species would interfere with Hep binding. CS-A and CS-C have one sulfate (two negative charges) per disaccharide unit and CS-D and CS-E have two sulfates (three negative charges) per disaccharide unit. Based on the results presented here and other supporting data (not shown), only DS and CS-E competed for Hep binding to HARE; CS-A, CS-C, and CS-D did not compete. The different CS types are all highly negatively charged and if sulfate group density were solely responsible for binding to HARE, then most or all the CS species should inhibit Hep binding to various degrees.
All of the classified scavenger receptors bind one or more forms of LDL such as AcLDL (Yuasa and Watanabe 2003) . Other groups have used either 125 I-AcLDL in direct binding assays with cells expressing Stabilin-2 (i.e., both isoforms) (Tamura et al. 2003) or AcLDL in indirect assays as a competitor for 125 I-AGE-BSA binding (Adachi and Tsujimoto 2002) . This is the first report to show the direct binding of 125 I-AcLDL by the 190-HARE and to assess competition with unlabeled GAGs. We found in this study that 125 I-AcLDL endocytosis by cells expressing 190-HARE was completely inhibited by Dx-S and partially inhibited by Hep and DS (Figure 8 ). The relative binding affinities of two ligands for the same site will determine the equilibrium distribution of both ligands. For example, in Figure 6 , B-HA was not competed by excess unlabeled DS, but some of the B-DS was competed by HA. This apparent discrepancy could be explained because HA binding to the HA site has a higher affinity (K D ∼18 nM) than DS binding to the HA site, or there is more than one DS-binding site along the receptor. A plateau effect in dose inhibition curves may indicate that one ligand interacts with only part of the binding site(s) of the other, which is thus still able to bind to HARE with good affinity. All of our data indicate that the AcLDL-binding site overlaps the Hep/DS sites and does not include or overlap with the HA-binding site.
The findings in this report may be very significant physiologically for several reasons. The simultaneous endocytosis of HA/CS and Hep/Hep-like proteoglycans is likely to be very important because these GAGs are continuously shed from extracellular matrixes (ECMs) in tissues throughout the body. That HA/CS and Hep can be simultaneously cleared from circulating lymph or blood by the same receptor indicates a strong biological "need" or evolutionary pressure to have an effective mechanism that removes multiple classes of ECM molecules in a coordinated way. We recently found that HARE mediates the activation of intracellular ERK-signaling pathways in response to HA binding (Kyosseva et al. 2008) . Thus, an additional exciting possibility is that in performing its function of clearing multiple GAGs, HARE may also provide a mechanism by which the body senses, evaluates, and responds to ECM turnover and degradation. Normally, proteoglycans, such as aggrecan, are partially degraded and replaced at a slow rate, but turn over much faster during inflammation and tissue remodeling. The large initial degradation products can be internalized by local cells or professional phagocytes in a tissue or flow/perfuse into the general systemic circulation, from which they are removed by HARE. HARE is the primary clearance receptor for CS proteoglycan fragments and Hep-bound proteins in the lymph and circulatory fluids, which constitute the systemic circulation.
Thus, HARE is an efficient scavenger for most of the GAGs, even those that are rare (e.g., CS-E; Ten Dam et al. 2007 ) and transiently produced in pathological situations. HA, CS, and Hep GAG chains may also serve as "handles" that bind with HARE and indirectly enable the clearance of a multitude of different growth factors, GAG-binding proteins, and other ECM proteins that are in complex with these GAGs. This "piggyback" clearance role for HARE would allow an efficient removal of the waste proteoglycan-associated material generated during infection, inflammation, development, tissue remodeling, and disease processes in distal tissues .
Materials and methods
Reagents and buffers
Purified unfractionated Hep (UFH) was from Celsus (Cincinnati, OH) and Sigma (St. Louis, MO), weight-average mass = 19 kDa. HA from Genzyme (Framingham, MA) was acid hydrolyzed under mild conditions (Raja et al. 1988 ), followed by neutralization to obtain a weight-average mass of 100 kDa. CS-A was from CalBiochem (La Jolla, CA) and DS, CS-C, CS-D, CS-E, and HS were from Seikagaku Corp. (Tokyo, Japan). All GAG preparations were analyzed by size exclusion chromatography/multiangle laser light scattering to determine concentration and weight-average polymer mass (Baggenstoss and Weigel 2006) . Biotinylated heparin and HA (B-Hep, B-HA) were prepared using the method of Yu and Toole (1995) , with slight modifications (Harris et al. 2007 ). AcLDL was from AbD Serotec (Raleigh, NC). Flp-In 293 cells, culture medium, transfection reagents, and plasmids were from Invitrogen/Gibco (Carlsbad, CA). pfu ultra HF was from Stratagene (La Jolla, CA). Classic Blue BX film was from MidSci (St. Louis, MO). Streptavidin (SA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (EDC), biotin-LC-hydrazide, sulfo-NHS-SS-biotin, SnakeSkin dialysis tubing (MWCO 3500) and chemiluminescence reagents, Luminol and Peroxide solutions, were from Pierce (Rockford, IL). Polysorp well strips were from Nunc (Roskilde, Denmark) and p-nitrophenylphosphate was from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, MD) . 125 I (100 mCi/mL; specific activity of >0.6 TBq/mg) in NaOH and Sepharose 6 Fast Flow (Nickel NTA) resin were from GE/Amersham Biosciences (Piscataway, NJ).
125 I-SA and 125 I-HA were prepared as described previously (Weigel 1980; McGary et al. 2003) . Concentrator/desalting Centricon devices were purchased from Amicon (Bedford, MA). Protein A/G agarose resin was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Tris-buffered saline containing Tween-20 (TBST) contains 20 mM Tris-HCl, pH 7.0, 150 mM NaCl, and 0.1% (v/v) Tween-20. Coating buffer for ELISA assays contains 15 mM Na 2 CO 3 , 36 mM NaHCO 3 , pH 9.5. Blocking buffer is TBST with 2% (w/v) BSA. Endocytosis medium is DMEM containing 0.05% BSA. Hank's balanced salts solution (HBSS) contains 5 mM KCl, 0.4 mM KH 2 PO 4 , pH 7.2, 0.8 mM MgSO 4 , 137 mM NaCl, 0.3 mM Na 2 HPO 4 , 5.5 mM Glucose, 1.26 mM CaCl 2 , 0.5 mM MgCl 2 , and 28 µM phenol red. SA-alkaline phosphatase conjugate and other salts and reagents were from Sigma (St. Louis, MO).
Preparation of constructs cDNA constructs encoding the secreted ecto-domains of the 315 kDa and 190 kDa human HARE were produced by the previous method in which the transmembrane and cytoplasmic domains were deleted, while retaining the Cterminal V5 and His 6 epitope tags (Harris et al. 2007) . A single primer (5 -GTGACCTTGACCCACACTGGATCCG-AAGGTAAGCCTATC-3 ) was used in individual mutagenic reactions with the wildtype HARE cDNAs (315-HARE in pcDNA5/FRT/V5/His, 190-HARE in pSecTag/FRT/V5/His) in an Ericomp thermocycler (18 cycles: 94
• C, 30 s; 63 • C, 30 s; 71
• C, 1 min/plasmid kb) using pfu ultra HF. To make the 190-HARE( Link) construct, a single primer (5 -CCACTTCCAGGATACCACTGTTCGGATGAAAGATGT GAACTGCACC-3 ) was used with the 190-HARE wildtype template to delete the Link domain (18 cycles: 94
• C, 30 s; 62
• C, 30 s; 71 • C, 1 min/plasmid kb). After these reactions, the plasmids were ethanol-precipitated and resuspended in 17 µL H 2 O, 2 µL NEB4 buffer, and 2.5 U of DpnI to cut template plasmids, while retaining intact mutant plasmids. After overnight incubation at 37
• C, the digestion mixtures were heated to 95
• C for 10 min and immediately transformed into TOP10 supercompetent Escherichia coli cells. Bacterial colonies were screened by a miniprep procedure, PCR, and sequencing to confirm the desired mutation. Plasmids containing correct mutations, open reading frames, and promoter regions were used to make stable cell lines as described in Harris et al. (2004 Harris et al. ( , 2007 .
Purification of s190-HARE s190-HARE was purified from the conditioned cell culture medium by immobilized Ni-chelate affinity chromatography. The media (250 mL) were prepared by the addition of 250 mM NaCl, 10 mM imidazole, and 10% glycerol to the indicated final concentration. Two milliliters of a 50% slurry of Ni-chelate resin was added, the mixture was incubated overnight at room temperature with slow rotation, and then passed through a 20 mL column to capture the resin. The resin was washed three times with one bed volume of 500 mM NaCl, 20 mM Na 2 HPO 4 , and 10 mM imidazole, pH 7.2. The s190-HARE protein was eluted with four successive 1 mL portions of the same buffer containing 400 mM imidazole. For efficient elution of s190-HARE, the first portion was added, the resin was stirred to create a suspension, and after incubation at 22
• C for 10 min, the column was then eluted. The next three 1 mL volumes were successively added, incubated for 10 min without mixing, and then eluted. This procedure recovered >90% of the protein associated with the resin. The four eluted fractions were pooled and concentrated to ∼0.2 mL using a 30 MWCO concentrator. The s190-HARE preparations were ∼10-20% pure, since some serum proteins in the media also adhered to the resin in a Ni-dependent fashion.
To further purify the s190-HARE protein for ELISA assays, the concentrated semi-pure s190-HARE was fractionated by 5% SDS-PAGE. The s190-HARE band, which separated distinctly from other bands, was identified in the gel by negative staining (using 4% CuCl 2 in water) and excised with a clean razor blade. The gel was minced to smaller pieces, which were destained with 0.25 M EDTA, 0.15 M Tris-HCl, pH 7.6, placed in a SnakeSkin dialysis bag with 5-10 mL 185 mM glycine, 2.5 mM SDS, and 25 mM Tris-HCl, pH 8.3, and electroeluted using a horizontal gel box for 16 h at 35 V, 4
• C. The solution within the dialysis bag was collected, concentrated, and washed as above with phosphate-buffered saline (PBS), and re-concentrated to 0.25 mL. Purity (∼99%) was verified by SDS-PAGE, silver staining, and Western blot analysis. Protein concentration was determined by the bicinchoninic acid method (Smith et al. 1985) .
ELISA-like assay
The purified s190-HARE protein was diluted in the coating buffer at 1.0 µg/mL and 200 µL was added to each Polysorp well, sealed with Scotch tape, and incubated at 22 o C for 16 h. All the following steps were performed at 37
• C. After coating, the Polysorp well surfaces were washed once with PBS and incubated with a 250 µL blocking buffer for 1.5 h. All ligands and SA-AP mixtures were diluted in the blocking buffer. Ligand solutions (200 µL) were incubated in each well for 2 h, removed, and the wells were washed six times with TBST, incubated for 1 h with SA-alkaline phosphatase, washed six times in TBST, and finally incubated with p-nitrophenylphosphate. The A 405 values of the solutions were determined several times within 1 h. Negative controls, used as blanks for the nonspecific binding of SA-alkaline phosphatase, were treated as above except for the addition of B-GAG.
Anti-HARE polyclonal antibody
The soluble ecto-domain of the 190-HARE protein (s190-HARE) was purified by electro-elution, as described above, and used for Ab production by Pocono Rabbit Farm and Laboratory, Inc. (www.prfal.com). Two rabbits were each initially injected with 0.2 mg s190-HARE in Freund's complete adjuvant followed by three boosts with 0.1 mg s190-HARE in Freund's incomplete adjuvant. IgG from the preimmune and postinjected rabbit serum was purified by protein A/G affinity chromatography according to the manufacturer's instructions. The eluted total immune, but not preimmune, IgG recognized the soluble and membrane-bound forms of both 190 kDa and 315 kDa HARE
